Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial

The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer. We evaluated maintenance olaparib plus bevacizumab in older patients in PAOLA-1. Baselin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2023-03, Vol.181, p.42-52
Hauptverfasser:	Sabatier, Renaud, Rousseau, Frédérique, Joly, Florence, Cropet, Claire, Montégut, Coline, Frindte, Johanna, Cinieri, Saverio, Guerra Alía, Eva M., Polterauer, Stephan, Yoshida, Hiroyuki, Vergote, Ignace, Colombo, Nicoletta, Hietanen, Sakari, Largillier, Rémi, Canzler, Ulrich, Gratet, Alain, Marmé, Frederik, Favier, Laure, Pujade-Lauraine, Eric, Ray-Coquard, Isabelle
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anemia Bevacizumab Bevacizumab - adverse effects BRCA1 protein Breast cancer Cancer Effectiveness Elderly Female Homologous recombination Homology Humans Hypertension Maintenance Monoclonal antibodies Mutation Neoplasm Recurrence, Local - drug therapy Olaparib Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Patients Phthalazines - adverse effects Piperazines - adverse effects Safety Subgroups Survival Targeted cancer therapy Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer. We evaluated maintenance olaparib plus bevacizumab in older patients in PAOLA-1. Baseline clinical and molecular data, and PFS, were compared between older (aged ≥65 years) and younger patients (
ISSN:	0959-8049 1879-0852
DOI:	10.1016/j.ejca.2022.11.029